ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$2.83
-0.13 (-4.39%)
Open$2.96
Previous Close$2.96
Day High$3.03
Day Low$2.75
52W High$4.60
52W Low$1.35
Volume—
Avg Volume1.76M
Market Cap224.52M
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+327.2% upside
Current
$2.83
$2.83
Target
$12.09
$12.09
$9.42
$12.09 avg
$15.53
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |
| Rev Growth | +12.9% | -8.9% | -3.6% |
| Debt/Equity | 0.35 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |